Details for Patent: 8,889,159
✉ Email this page to a colleague
Which drugs does patent 8,889,159 protect, and when does it expire?
Patent 8,889,159 protects EPCLUSA, HARVONI, SOVALDI, and VOSEVI, and is included in seven NDAs.
Protection for EPCLUSA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-five patent family members in forty-one countries.
Summary for Patent: 8,889,159
| Title: | Compositions and methods for treating hepatitis C virus |
| Abstract: | Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period. |
| Inventor(s): | Cleary; Darryl G. (Chapel Hill, NC), Reynolds; Charles J. (Greenville, NC), Berrey; Miriam Michelle (Durham, NC), Hindes; Robert G. (Skillman, NJ), Symonds; William T. (San Francisco, CA), Ray; Adrian S. (Redwood City, CA), Mo; Hongmei (Palo Alto, CA), Hebner; Christy M. (Belmont, CA), Oliyai; Reza (Burlingame, CA), Zia; Vahid (San Carlos, CA), Stefanidis; Dimitrios (Mountain View, CA), Pakdaman; Rowchanak (San Carlos, CA), Casteel; Melissa Jean (Burlingame, CA) |
| Assignee: | Gilead Pharmasset LLC (Foster City, CA) |
| Application Number: | 13/686,664 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,889,159 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Process; Use; |
Drugs Protected by US Patent 8,889,159
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-001 | Jun 10, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-002 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| Gilead Sciences Inc | HARVONI | ledipasvir; sofosbuvir | PELLETS;ORAL | 212477-001 | Aug 28, 2019 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,889,159
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 088580 | ⤷ Sign Up | |||
| Argentina | 089578 | ⤷ Sign Up | |||
| Australia | 2012308295 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
